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Are We Achieving the Current Waiting Time Targets in
Lung Cancer Treatment?
Sam Janes, PhD, MRCP,* and Stephen Spiro, MD, FRCP†
Most large hospitals in the United Kingdom will see 100 to 150 new cases of lungcancer a year, mostly as new outpatient referrals, but as much as 30% of patients are
admitted through the emergency department to be cared for by a variety of disciplines. So,
it is a significant load, and, for a disease for which the median survival is 8 to 9 months,
it needs prompt and expert attention. Before the National Cancer Plan in 1997, there was
no system of prioritization for suspected cancer referrals, and for those patients admitted,
much depended on the specialty in charge as to what might happen and at what pace (let
alone whether a respiratory referral was made!). The British government has made cancer
care a priority, basically because British 5-year survival figures were considered inferior
to those of other comparable European and western countries for several cancer types and
because there was inadequate order in the organization of day-to-day cancer care. As
discussed in the commentary by Devbhandari et al. in this issue of The Journal, the
expectation is for patients suspected to have lung cancer to be seen within 14 days of a
referral, diagnosed and staged with a decision for initial treatment within 31 days, and
beginning treatment within 62 days of initial referral.1,2 In addition to forming regional
cancer centers, each with several units (district general hospitals), the development of
weekly multidisciplinary team (MDT) meetings and provision of clinical coordinators to
run these meetings, follow patients and speed up tests, the setting has been laid for
improvement.
Whether lung cancer outcomes have improved is hard to say and depends on how
one defines improvement. Clearly, for the patient there has been a remarkable speeding up
of initial consult, having tests and biopsies, and being brought to a MDT for a treatment
discussion. Most agree that there is little delay in the initial clinic visit, although many
urgent referrals are clearly not, and there is considerable abuse of the system. This may
not be the fault of the referring community physician, as lung cancer has few specific
symptoms, and the average general practitioner may see only one or two new cases a year,
among hundreds with cough, chest infection, wheeze, etc.
Incumbent on rapid assessment has been the reorganization of imaging and endos-
copy departments. Some centers have instituted a one-stop approach with same-day
computed tomography (CT), discussion, and transthoracic or bronchoscopic biopsy.
Others have reserved CT slots and hold weekly meetings to arrange the most appropriate
route for diagnosis and staging, again with reserved places. For the great majority of cases,
a CT and single biopsy procedure yields the diagnosis, and well within 31 days.
Difficulties arise if initial biopsy approaches are inconclusive and/or sophisticated staging
is needed with positron emission tomography, with which there can be significant delays
because of the national shortage of these scanners.3
Once the decision to treat is made, there is a month to do so. This is not challenging
for thoracic surgery or for chemotherapy, as the guidelines state that patients with small
cell lung cancer should begin chemotherapy within 1 week, and patients with non-small
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cell lung cancer should begin chemotherapy within 4 weeks.
Radiotherapy departments may cause delays in radical field
planning because often there is a failure to prioritize lung
cancer. However, all this is achievable.
Will the changes make any difference? Yes, it will
make the patient journey faster and more efficient, although
patients may not want to proceed at this speed and may lose
contact with their initial physician, risking communication
problems, at a time in their lives when huge decisions need to
be made. The MDT and the organization around it make it
difficult for a patient to drop out or be forgotten. It also
provides a conduit for all patients with lung cancer to be
presented, preventing other medical groups from hanging
onto these cases.
The funding of a national data set for lung cancer
(LUCADA) will provide a unique opportunity to follow the
standards of lung cancer care in the United Kingdom. More
than 800 patients a month are being entered from all over the
country and this should now increase as data entry becomes
mandatory. However, the most important question is whether
this political innovation to improve the patient journey will
improve survival for the disease, which is the main objective.
Improving the patient journey alone may improve survival for
a few patients previously not offered prompt expert exposure
who may now undergo an operation, radical radiotherapy,
etc. However, the most important determinant of survival is
the innate biology of the tumor. Rapidly growing disease is
unlikely to be converted from incurable to curable by a few
weeks’ faster detection, and slowly growing cancers may still
be curable if missed for 6 months. With doubling rates of 30
to 120 days, and the average lung cancer presenting at 3 to 4
cm in diameter on a chest radiograph, 35 volume doubling
times (3 to 12 years) will have passed before diagnosis,
making the weeks saved by the National Cancer Plan irrele-
vant. Nevertheless, it has introduced an improving system of
care, a welcome reorganization of MDT working, an oppor-
tunity to improve entry of patients into clinical trials, and a
national data set that will become the benchmark for future
improvements in care but probably not have much effect on
overall cure rates.
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